Silver Book Fact

Using medical imaging to diagnose and treat stroke leads to better outcomes and shorter hospital stays, which yields a net economic benefit of about $8 billion over 10 years.

Johnston S, Rootenberg J, Katrak S, Smith W, et al. Effect of a U.S. National Institute of Health Programme of Clinical Trials in Public Health and Costs. The Lancet. 2006; 367: 1319-27. https://pubmed.ncbi.nlm.nih.gov/16631910/

Reference

Title
Effect of a U.S. National Institute of Health Programme of Clinical Trials in Public Health and Costs
Publication
The Lancet
Publication Date
2006
Authors
Johnston S, Rootenberg J, Katrak S, Smith W, et al.
Pages
1319-27
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Primary angioplasty reduces 30-day mortality risk by 34% to 50%.  
  • Since 1970, reduced mortality from heart disease has increased the value of life by about $1.5 trillion per year. The value of improvements in health care over the 20th century…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.